Previous reports demonstrated an association between reduced ITPase activity and treatment-induced thrombocytopenia [29,45], likely in relation to the decline in Hb, or due to the increased stimulation of megakaryocyte-erythroid progenitor cells by erythropoietin production [46]. Here, EPO is linked to Thrombocytopenia.